Ascendis Pharma published an investor presentation highlighting Week 78 results from the Phase 2 COACH trial in pediatric achondroplasia.
Once-weekly TransCon CNP with TransCon hGH maintained annualized growth velocity at or above the 97th percentile for average-stature children through Week 78.
Achondroplasia height Z-scores rose through Week 78, described as roughly triple the effect seen with TransCon CNP monotherapy in cross-trial comparisons.
Safety through Week 78 was consistent with the two monotherapies; 0 discontinuations due to adverse events; 0 treatment-related serious adverse events.
All 21 children completed 78 weeks of treatment, with 100% remaining in the trial.
ASND•
